| | First author, year | No. of participants randomized/assessed; dropouts | Age; Gender (M/F) | COPD stage | Duration of condition
(years) | Treatment duration; follow-up duration
(months) |
| | Bai SR, 2016 | T:90/85;5 | T:58.7(12.5);49/41 | II,III | T:6.5(3.3) | T:6;0 | | C:90/83;7 | C:59.3(13.2):51/39 | C:6.3(3.2) | C:6;0 |
| | Cao DC, 2016 | T:50/50;0 | T:66.33(4.21);30/20 | II | NS | T:3;0 | | C:50/50;0 | C:64.45(5.11);28/22 | C:3:0 |
| | Dong KZ, 2016 | T:25/25;0 | T:65.2(3.2);18/7 | II,III | NS | T:3;0 | | C:25/25;0 | C:66.8(2.7);17/8 | C:3:0 |
| | Fei DL, 2010 | T: 45/45;0 | T:59.7(4.5);28/17 | II,III | T:10.5(4.9) | T: 3;0 | | C: 45/45;0 | C:57.9(4.1);26/19 | C:11.5(5.2) | C: 3;0 |
| | He WJ, 2010 | T: 24/22;2 | T:55.36(9.03);15/7 | II,III | T:12.22(2.75) | T: 3;0 | | C: 24/23;1 | C:57.13(8.77);17/6 | C:11.56(3.08) | C: 3;0 |
| | Hu QG, 2012 | T: 51/51;0 | T:65.41(12.23);34/17 | II,III | NS | T: 6;0 | | C: 50/50;0 | C:64.86(11.84);34/16 | C: 6;0 |
| | Huang DH, 2005 | T: 32/32;0 | T:69.5(11.8);21/11 | II,III | T:8.5(3.2) | T: 3;0 | | C: 31/31;0 | C:68.8(10.6);23/8 | C:8.3(3.5) | C: 3;0 |
| | Liu JS, 2014 | T: 40/40;0 | Total:64.2(2.4);82/38 | II,III | Total:15.2(3.9) | T: 12;0 | | C: 40/40;0 | C: 12;0 |
| | Luo SW,2015 | T: 51/51;0 | T:72.3(8.5);33/18 | II,III | T:14.7(5.3) | T: 2;0 | | C: 51/51;0 | C:73.5(8.9);34/17 | C:15.1(5.7) | C: 2;0 |
| | Tang CY, 2009 | T: 30/30;0 | T:63.2;27/3 | II,III | T:7.2 | T: 6;6 | | C: 30/30;0 | C:65.5;26/4 | C:7.5 | C: 6;6 |
| | Wu HL, 2016 | T:46/46;0 | T:66.58(7.12);31/15 | II,III | T:5.82(1.64) | T:2;0 | | C:32/32;0 | C:66.34(7.09);21/11 | C:6.03(1.71) | C:2;0 |
| | Xin DY, 2015 | T: 41/41;0 | T:58.6;21/20 | II,III | T:10.2 | T: 1;0 | | C: 39/39;0 | C:57.9;19/20 | C:10.8 | C: 1;0 |
| | Yao JF, 2013 | T:30/27;3 | T:67.48(6.99);18/9 | III | T:6.33(4.01) | T: 3;0 | | C:30/25:5 | C:67.68(7.76);18/7 | C:4.68(3.16) | C: 3;0 |
| | Zhou Y, 2014 | T:50/50;0 | T:62.8(6.2);29/21 | II | T:14.5(8.5) | T: 6;6 | | C:50/50;0 | C:61.6(7.4);30/20 | C:13.5(9.5) | C: 6;6 |
|
|
